PDS Biotechnology

Update in progress

PDSB (NasdaqCM)

PDS Biotechnology is a clinical-stage biopharmaceutical company focused on targeted cancer immunotherapies. Its lead candidate, Versamune HPV, is in a Phase II trial for head and neck, cervical, anal, vaginal, vulvar, and penile cancers. Preclinical programs include PDS0102 and PDS0103, for various solid tumors, and PDS01ADC, an interleukin-12–based antibody-drug conjugate. PDS0202 is an investigational influenza vaccine. Collaborations include NIH, Merck Eprova, DHHS, and MSD. Founded 2005, Princeton, NJ.